about
Selective CCK-A but not CCK-B receptor antagonists inhibit HT-29 cell proliferation: synergism with pharmacological levels of melatoninDysfunctional Coq9 protein causes predominant encephalomyopathy associated with CoQ deficiencyEffects of some synthetic kynurenines on brain amino acids and nitric oxide after pentylenetetrazole administration to rats.Characterization of nocturnal ultradian rhythms of melatonin in children with growth hormone-dependent and independent growth delay.The clinical heterogeneity of coenzyme Q10 deficiency results from genotypic differences in the Coq9 gene.Melatonin protects rats from radiotherapy-induced small intestine toxicity.Melatonin enhances neural stem cell differentiation and engraftment by increasing mitochondrial function.Melatonin role in the mitochondrial function.CoQ deficiency causes disruption of mitochondrial sulfide oxidation, a new pathomechanism associated with this syndrome.Mitochondrial DNA and inflammatory diseases.Exercise and melatonin in humans: reciprocal benefits.Extrapineal melatonin: sources, regulation, and potential functions.Melatonin in the oral cavity: physiological and pathological implications.A review of the melatonin functions in zebrafish physiology.Protective actions of melatonin and growth hormone on the aged cardiovascular system.Melatonin, clock genes and mitochondria in sepsis.The benefits of four weeks of melatonin treatment on circadian patterns in resistance-trained athletes.Permeabilized myocardial fibers as model to detect mitochondrial dysfunction during sepsis and melatonin effects without disruption of mitochondrial network.Same molecule but different expression: aging and sepsis trigger NLRP3 inflammasome activation, a target of melatonin.Cell protective role of melatonin in the brain.Disruption of the NF-κB/NLRP3 connection by melatonin requires retinoid-related orphan receptor-α and blocks the septic response in mice.Mitochondrial impairment and melatonin protection in parkinsonian mice do not depend of inducible or neuronal nitric oxide synthasesIdentification of mitochondrial deficits and melatonin targets in liver of septic mice by high-resolution respirometry.Melatonin and its brain metabolite N(1)-acetyl-5-methoxykynuramine prevent mitochondrial nitric oxide synthase induction in parkinsonian mice.Synergism between melatonin and atorvastatin against endothelial cell damage induced by lipopolysaccharide.Oxidative stress status, clinical outcome, and β-globin gene cluster haplotypes in pediatric patients with sickle cell disease.Antioxidant defence and inflammatory response in professional road cyclists during a 4-day competition.Melatonin treatment normalizes plasma pro-inflammatory cytokines and nitrosative/oxidative stress in patients suffering from Duchenne muscular dystrophy.Fluorinated indazoles as novel selective inhibitors of nitric oxide synthase (NOS): synthesis and biological evaluation.Redox status and antioxidant response in professional cyclists during training.Effect of propranolol plus exercise on melatonin and growth hormone levels in children with growth delay.Calcium-dependent effects of melatonin inhibition of glutamatergic response in rat striatum.Melatonin and beta-endorphin changes in children sensitized to olive and grass pollen after treatment with specific immunotherapy.Inhibition of nNOS activity in rat brain by synthetic kynurenines: structure-activity dependence.Circadian rhythms of dopamine and dihydroxyphenyl acetic acid in the mouse striatum: effects of pinealectomy and of melatonin treatment.Extrapineal melatonin: analysis of its subcellular distribution and daily fluctuations.Synergistic effects of melatonin and deprenyl against MPTP-induced mitochondrial damage and DA depletion.Characterization of melatonin high-affinity binding sites in purified cell nuclei of the hamster (Mesocricetus auratus) harderian gland.Changes in brain amino acids and nitric oxide after melatonin administration in rats with pentylenetetrazole-induced seizures.Relationship between salivary melatonin levels and periodontal status in diabetic patients.
P50
Q28271296-F675246E-0645-4D33-B6FF-310D519E6C33Q28588893-3A801F4F-90D9-42C2-BDF4-0D493B9A886FQ30919491-8E6EEF7C-FF31-45A8-89CC-B0D02D87D6C4Q32131591-0B4EEB90-E0A9-4EFB-B373-3D1157B93213Q35822596-873EB929-600B-4023-92DE-3832182CFA7FQ36344749-667D1652-F4B1-4BCE-BFB5-E7323D729E2CQ36351040-2EB6846D-EF27-46EA-9E3D-D18066A614CFQ36664479-2DAFDF6C-9D21-4E2E-ADA5-5CF2D2DF00B7Q37555654-A5E8EDD5-A6EE-4EE8-A0C2-457336E842ABQ37898562-A7F308EA-92E6-44A4-BCBC-A9DB4BA46E26Q37919169-F0AB69B7-2A71-4D3A-AEBA-69659F7D3312Q38189699-BB24B031-EA54-44E0-AD5C-44E62FA30EA2Q38199125-9F7FB01A-AD7C-4A3C-9F5E-CC1E93C1C4CEQ38219607-4BF683C5-81DE-4A75-92A0-E9475B4814E5Q38267485-FCE215EE-9F2F-4635-A932-89852F8D0E5BQ38635632-8944EB60-9159-47EA-BEB9-E0FAF572A3D1Q40548477-A6735222-0F77-467D-AFBD-40DEF4288D70Q40839400-6F1A041D-687B-4524-928A-40648F3D4930Q40866395-A0E18CBC-7081-4898-A8E1-78A2EFC2443FQ40975753-5DD4C9EF-BA76-4D98-946D-05E7EB8F29ABQ41183481-CC161AFD-E6A9-46B9-879D-08CB323E7AF1Q41363567-CDCE990F-9355-4CC6-91F1-EAA5D12CC7B6Q41603873-B67AA485-0A4C-49D7-ADCA-6114075ADEDEQ42168350-EB6F13A1-8BEB-4452-962B-6980522C5391Q42735728-DE1D5472-5779-4104-A804-4C297E29F9C8Q42905697-2373B7C4-FAB0-4B4D-A70D-C39B47ED9B7FQ42945717-218602D3-CEB4-4E1A-9569-20719626F0E3Q43139004-DF414A7E-42AE-46FA-AC50-71A373E282FBQ43292347-3877F6DF-AF65-4408-8091-8E4AF80C0DA5Q43520535-C82C1433-FADE-450A-8A29-EAFC7B68BB19Q43554738-428154D7-F6C0-4934-B26F-3D745AE57B69Q43591969-F58940D3-DAA1-40AC-9350-4182D262DD8FQ43771648-5BF9CC11-BB1C-42FA-950B-C35A879B1CA3Q43849702-24D29BF3-65D8-4E71-88A2-D029AD2A3592Q43933401-106079A6-B8CA-470C-A481-AA2C9FA86F52Q44208373-95B3CF1B-EAB1-409E-BA74-28B91752135AQ44324477-2AD4DC9B-6FCC-47BB-8C69-43320DADE782Q44340074-EA1E0778-6174-4D4B-AA6E-C59FCE04E656Q44489325-74B4DA2E-1381-4186-B07C-1923445B580FQ44604263-BD5F939A-8750-4BD2-BCF1-ED69A43B6F14
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Germaine Escames
@ast
Germaine Escames
@en
Germaine Escames
@es
Germaine Escames
@sl
type
label
Germaine Escames
@ast
Germaine Escames
@en
Germaine Escames
@es
Germaine Escames
@sl
prefLabel
Germaine Escames
@ast
Germaine Escames
@en
Germaine Escames
@es
Germaine Escames
@sl
P1053
N-7501-2016
P106
P1153
6701603739
P21
P31
P3829
P496
0000-0003-1256-7656
P569
2000-01-01T00:00:00Z